PLX5622

CAS No: 1303420-67-8
Appearance: Pale yellow powder
Standard: Enterprise Standard
Supply Ability:5000g per month
Shelf Life: Two years
Payment: T/T, LC or DA
Delivery Time: Ready Stock in Local Warehouse, 1-3 days
Origin: China
Shipping: DHL, FedEx, TNT, EMS, By Sea, By Air
Supply laboratory personnel for research purposes, not for sale to patients
  • Fast Delievery
  • Quality Assurance
  • 24/7 Customer Service
Product Introduction

We supply PLX5622

We're pleased to offer PLX5622, a top- quality product designed to meet your requirements. Our product is a high- performance result, manufactured using the rearmost technology and designed to deliver harmonious results. This product is perfect for a wide range of operations, and it's suitable for use in a variety of diligence. When you choose our product, you can rest assured that you're getting a decoration- quality product that's completely tested and certified to meet assiduity norms. Order now and witness the trustability, performance, and quality that only our PLX-5622 can give.

 

What's PLX5622 ?

It is an experimental medicine with the eventuality to revise the treatment of neurodegenerative conditions similar as Alzheimer's and Parkinson's conditions. It's a small patch that works by inhibiting the function of a specific type of vulnerable cell called microglia, which play a crucial part in neuroinflammation and neuronal damage in these conditions. it is a product of Plexxikon Inc and has been estimated in clinical and preclinical studies to assess its safety, efficacity and pharmacokinetic parcels.

it is a picky asset of colony- stimulating factor 1 receptor( CSF1R), which is expressed substantially in microglia. By blocking CSF1R, it effectively depletes microglia from the brain without affecting other vulnerable cells. This targeted approach reduces neuroinflammation, promotes neuroprotection, and enhances cognitive function in colorful beast models of neurodegenerative conditions. In addition to its remedial eventuality, it has also been used as a exploration tool to probe the part of microglia in brain functions and conditions.

In clinical trials, it has shown promising results in reducing neuroinflammation in cases with Alzheimer's complaint and perfecting their cognitive performance. It has also been tested in beast models of Parkinson's complaint, multiple sclerosis, traumatic brain injury, neuropathic pain, and other neurological diseases, where it has demonstrated salutary goods on complaint pathology and behavioral issues.

it is available as a white to out-white greasepaint for exploration purposes only. It's water-answerable and can be administered orally or by injection to laboratory creatures. its chemical structure has been determined by NMR,X-ray crystallography, and MS. Its molecular weight is484.4 g/ spook, and its chemical formula is C21H18Cl2N6O. it is stable under normal storehouse conditions and can be stored at room temperature in a dry and dark place.

In conclusion, it is a new remedial agent that targets microglia and has the implicit to treat a range of neurodegenerative conditions. Its picky inhibition of CSF1R and its favorable pharmacological profile make it a promising seeker for farther clinical development.

 

Basic Information

Product Name: PLX5622

CAS No: 1303420-67-8

Appearance: Pale yellow powder

MF:C21H19F2N5O

MW:395.41

MDL No.:MFCD32201039

Structural formula:

product-1-1

Assay: 98% HPLC

Solubility: In DMSO

Origin: China

Application: Supply laboratory personnel for research purposes, not for sale to patients

Delivery Time: in stock

 

Technical Specification

Item

Specification

Results

Appearance

Pale yellow powder

Complies

Purity(HPLC)

≥98%

98.5%

Conclusion

It complies with the requirements

Package: 1g;100g; or according to your demands

Storage method: Freeze dry at -20 ℃ and store in a dark place

Shelf Life 24 months

 

Biological Activity 

PLX5622 is a largely potent and picky asset of colony- stimulating factor 1 receptor( CSF1R) that holds immense remedial eventuality in the treatment of a variety of conditions similar as Alzheimer's complaint, multiple sclerosis, and cancer.

As a CSF1R asset, it has demonstrated outstanding natural exertion by widely targeting CSF1R- expressing cells similar as microglia, towel macrophages, and some cancer cell types. By inhibiting CSF1R signaling, it is suitable to reduce the number and exertion of these cells, which in turn leads to a range of remedial benefits.

In preclinical studies, it has shown strong eventuality for mollifying neuroinflammation and neurodegeneration associated with Alzheimer's complaint, as well as guarding against demyelination and axonal damage in multiple sclerosis. also, it has also shown pledge in reducing the progression and invasiveness of certain cancer types, particularly those that calculate on CSF1R signaling for growth and survival.

One of the crucial advantages  is its high selectivity for CSF1R, which minimizes the threat of out- target goods and toxin. also, the emulsion has excellent pharmacokinetic parcels, with a half- life of roughly 9 hours and good oral bioavailability. These parcels make it a largely promising seeker for farther clinical development and eventual commercialization.

In summary,it is a largely potent and picky CSF1R asset that holds immense remedial eventuality in addressing a range of conditions including Alzheimer's complaint, multiple sclerosis, and cancer. Its strong natural exertion, selectivity, and favorable pharmacokinetic parcels make it a promising seeker for farther disquisition.

 

In vitro exploration  

Introducing the PLX-5622 in vitro exploration tool, designed for perfection and delicacy in laboratory studies. This slice- edge tool allows experimenters to explore the goods of targeting microglia in the brain, which can help uncover the mechanisms behind neuroinflammation and neurodegenerative conditions similar as Alzheimer's and Parkinson's.

it is a important medicine that widely depletes microglia in the brain, offering experimenters a tool to study the part of these cells in the environment of colorful conditions. This exploration tool enables in vitro studies that can accelerate the discovery of remedial results for ruinous neurological diseases.

it exploration tool is especially designed to meet the requirements of ultramodern scientists and experimenters, allowing them to explore microglial biology and the part of microglial activation in brain function, while furnishing a deeper understanding of how neurodegenerative conditions develop. With it, experimenters can conduct largely targeted and accurate studies of the brain's microglia, leading to new perceptivity and discoveries.

erected using state- of- the- art technology and styles, it exploration tool is an inestimable addition to any neurological exploration laboratory. It provides experimenters with a sophisticated tool to dissect microglial activation in the brain, therefore advancing our understanding of neurological diseases.

In summary, it exploration tool is a sophisticated and accurate way to study microglial exertion in the brain and can help experimenters identify implicit remedial targets for treating neuroinflammatory and neurodegenerative conditions. therefore, making this tool an exceptional investment for neurological exploration labs looking to achieve groundbreaking discoveries.

 

In vivo exploration PLX5622

PLX5622 is a small patch asset that has been used in preclinical exploration for targeting microglial cells. Microglia are the resident vulnerable cells of the central nervous system and play a critical part in maintaining brain homeostasis. it specifically targets CSF1R( colony- stimulating factor 1 receptor), which is expressed on the face of microglia.

In vivo exploration using it generally involves administering the emulsion to beast models, similar as mice, to study the goods of microglial reduction or modulation. By inhibiting CSF1R, PLX5622 can lead to the reduction of microglia, allowing experimenters to probe the part of these cells in colorful complaint models, including neurodegenerative diseases, neuroinflammation, and brain injury.

Studies using it in vivo have contributed to our understanding of the complex functions of microglia and their implicit as remedial targets in neurological conditions. This line of exploration holds pledge for developing new treatments for a range of brain- related diseases.

 

Target points

Target

Value

CSF-1R (Cell-free assay)

0.016 μM

FLT3 (Cell-free assay)

0.39 μM

KIT (Cell-free assay)

0.86 μM

AURKC (Cell-free assay)

1 μM

KDR (Cell-free assay)

1.1 μM

 

Why Choose Xi'an Yihui?

Customer feedback

7 Customer Comments.webp

Xi'an Yihui certificates

8 certificate.webp

Welcome to Xi'an Yihui Factory

9 Factory & Warehouse.webp

Our Advantage

Rich experience: we have 13 Years of professional experience;

Customers all over the world: sell to more than 100 countries;

Provide diversified products: the products have been applied to all major international brands in the fields of drugs, dietary supplements, cosmetics, animal nutrition and functional food.

Price advance: low MOQ with competitive price;

Quality certification: ISO; Halal; Kosher certified

After-sales service: Professional team 7*24 hours customer service.

Contact Us:

Yihui takes pride in being a trusted PLX5622 manufacturer and supplier. To acquire this groundbreaking product or discuss your specific requirements, contact us immediately at sales@yihuipharm.com. Rest assured, with Yihui, you're accessing a product of unparalleled quality, backed by certifications that underscore our commitment to excellence in the global market.

hot tags: PLX5622,China, manufacturers, suppliers, wholesale, buy, factory, Bulk, price, for sale

Send Message

If you have any enquiry about quotation or cooperation, please feel free to email us at E-mailor use the following enquiry form. Our sales representative will contact you within 24 hours.Thank you for your interest in our products.

Send